Free Trial

Enliven Therapeutics (ELVN) Expected to Announce Quarterly Earnings on Tuesday

Enliven Therapeutics logo with Medical background

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.12 during trading hours on Friday, hitting $18.51. The company had a trading volume of 511,962 shares, compared to its average volume of 260,554. Enliven Therapeutics has a 1-year low of $13.30 and a 1-year high of $30.03. The business has a 50 day moving average of $19.06 and a 200-day moving average of $22.04. The company has a market cap of $908.21 million, a PE ratio of -9.74 and a beta of 1.07.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the sale, the insider now directly owns 997,688 shares in the company, valued at approximately $16,032,846.16. The trade was a 0.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This trade represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.

Check Out Our Latest Stock Analysis on ELVN

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Articles

Earnings History for Enliven Therapeutics (NASDAQ:ELVN)

Should You Invest $1,000 in Enliven Therapeutics Right Now?

Before you consider Enliven Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.

While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines